The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-30. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
The beneficial effect of exercise on hyperinsulinemia was shown in a study in 2009, where they found that improving fitness through exercise significantly decreases blood insulin concentrations. Moreover, a diet that consists of high amounts of carbs have been linked to weight gain and obesity in rodents. Although this has not been tested in humans, it is assumed that it could aid with the prevention of weight gain in humans, and possibly obesity. Medications have also been studied to treat hyperinsulinemia, although these might have some side effects, these could be used as an alternative.
"It seems to me", Mellanby wrote to Florey, "that the line of work you are suggesting will be interesting and may prove to be of practical importance." Florey felt that far more would be required. On 1 November 1939, Henry M. "Dusty" Miller Jr from the Natural Sciences Division of the Rockefeller Foundation paid Florey a visit. Miller encouraged Florey to apply for funding from the foundation and supported his application. "The work proposed", Florey wrote in the application letter, "in addition to its theoretical importance, may have practical value for therapeutic purposes." His application was approved, with the foundation allocating US$5,000 (£1,250) per annum for five years. The Oxford team's first task was to obtain a sample of penicillin mould. This turned out to be easy. Georges Dreyer, Florey's predecessor, had obtained a sample of the mould in 1930 for his work on bacteriophages, viruses that infect bacteria. Dreyer had lost interest in penicillin when he discovered that it was not a bacteriophage, but he had continued to cultivate it. Dreyer had died in 1934, but Campbell-Renton had continued to culture the mould and was able to supply it to the Oxford team. The next task was to grow sufficient mould to extract enough penicillin for laboratory experiments. The mould was cultured on a surface of liquid Czapek-Dox medium. Over the course of a few days it formed a yellow gelatinous skin covered in green spores. Beneath this, the liquid became yellow and contained penicillin. The team determined that the maximum yield was achieved in ten to twenty days.
== Notable people == Eric Decker, National Football League player Alvin Ganzer (1911–2009), film director, born in Cold Spring John J. Kinzer (1891–1986), Minnesota state legislator and farmer Doug Stang, Minnesota state legislator Justin Stommes, professional basketball player; graduated from Rocori High School
He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 season, during which time he had intended to coach Nuriootpa Rovers Football Club in the Barossa Light & Gawler Football League. Slattery completed a Bachelor of Agricultural Science from the University of Melbourne in late 2010, and also undertook a short course in Wine Appreciation and Making at Armadale Cellars in 2011. In recognition of his success in juggling football and study commitments, Slattery was awarded the AFL Players Association's Education and Training Excellence Award in 2011.
Sources: en.wikipedia.org
All mRNA templates used for mRNA display technology have puromycin at their 3' end. As translation proceeds, the ribosome moves along the mRNA template, and once it reaches the 3' end of the template, the fused puromycin will enter ribosome's A site and be incorporated into the nascent peptide. The mRNA-peptide fusion is then released from the ribosome (Figure 1). To synthesize an mRNA-peptide fusion, the fused puromycin is not the only modification to the mRNA template. Oligonucleotides and other spacers need to be incorporated along with the puromycin to provide flexibility and proper length for the puromycin to enter the A site. Ideally, the linker between the 3' end of an mRNA and the puromycin has to be flexible and long enough to allow the puromycin to enter the A site upon translation of the last codon. This enables the efficient production of high-quality, full-length mRNA-peptide fusions. Rihe Liu et al. optimized the 3'-puromycin oligonucleotide spacer. They reported that dA25 (a nucleotide sequence of 25 deoxyadenosine residues) in combination with a Spacer 9 (Glen Research), and dAdCdCP at the 5' terminus worked the best for the fusion reaction. They found that linkers longer than 40 nucleotides and shorter than 16 nucleotides showed greatly reduced efficiency of fusion formation. Also, when the sequence rUrUP was present adjacent to the puromycin, fusion did not form efficiently.
Following the successful nomination, Collins said she was "surprised and overwhelmed", and although she "couldn't see why someone would want to nominate [her]", she added that she was "all about world peace [...] love conquers all. Peace is everything".
=== Pharmacokinetics === Gabapentin is absorbed from the intestines by an active transport process mediated via an amino acid transporter, presumably, LAT2. As a result, the pharmacokinetics of gabapentin is dose-dependent, with diminished bioavailability and delayed peak levels at higher doses. The oral bioavailability of gabapentin is approximately 80% at 100 mg administered three times daily once every 8 hours, but decreases to 60% at 300 mg, 47% at 400 mg, 34% at 800 mg, 33% at 1,200 mg, and 27% at 1,600 mg, all with the same dosing schedule. Drugs that increase the transit time of gabapentin in the small intestine can increase its oral bioavailability; when gabapentin was co-administered with oral morphine, the oral bioavailability of a 600 mg dose of gabapentin increased by 50%. Gabapentin at a low dose of 100 mg has a Tmax (time to peak levels) of approximately 1.7 hours, while the Tmax increases to 3 to 4 hours at higher doses. Food does not significantly affect the Tmax of gabapentin and increases the Cmax and area-under-curve levels of gabapentin by approximately 10%. Gabapentin can cross the blood–brain barrier and enter the central nervous system. Gabapentin concentration in cerebrospinal fluid is approximately 9–14% of its blood plasma concentration. Due to its low lipophilicity, gabapentin requires active transport across the blood–brain barrier. The LAT1 is highly expressed at the blood–brain barrier and transports gabapentin across into the brain.
==== Democratic reaction ==== The narrow passage of OBBBA led to internal backlash and division in the Democratic Party. Three elderly Democratic representatives (Raúl Grijalva of Arizona, age 77; Sylvester Turner of Texas, age 70; and Gerry Connolly of Virginia, age 75) died in the first five months of 2025. If any of the three had been alive when the vote was taken, the result of the vote could have been different. The vote "quickly reignited an intraparty debate about gerontocracy and aging politicians clinging to power".
==== Climbing Chimborazo ==== Humboldt and Bonpland began their ascent of Chimborazo from the plain of Tapia, situated at 3,163 yards (2,892 m) above sea level. The route led through a high plateau between the eastern and western chains of the Andes, passing sparse vegetation such as cacti and Schinus molle, as well as herds of llamas. The altitude caused agricultural difficulties, since nocturnal cooling often resulted in frozen crops. Before reaching Calpi, they visited Lican, once an important settlement before the Spanish conquest, but now reduced to a small village. Indigenous people believed that wild llamas on Chimborazo descended from domesticated herds scattered after the destruction of Lican. The travelers spent the night in Calpi, which Humboldt measured at 3,452 yards (3,157 m) meters above sea level. On June 23, they began the main phase of their Chimborazo expedition, choosing a south-southeast route favored by their Indigenous guides, though only a few guides had reached the limits of the perpetual snow. Humboldt observed that Chimborazo was surrounded by step-like, grass-covered plateaus, which he compared to former lake beds and similar terrace formations in the Alps. The flora of these grasslands was dominated by grass species common in northern Europe, with few dicotyledonous herbs and limited floral diversity compared to other Andean peaks. Temperatures in the region varied strongly between day and night, and the mean annual temperature at this elevation was approximately nine degrees Celsius.
Sources: en.wikipedia.org
However, sulfur dioxide added earlier in the malolactic fermentation process limits diacetyl production by inhibiting the bacteria and limiting their activity in its entirety, including the conversion of malic to lactic acid.
In another study, researchers evaluated synthetic platelet (SP) nanoparticles in mouse models of von Willebrand disease (vWD). In vitro, SPs enhanced thrombus formation under vWF-deficient conditions using human platelets. In vivo, SP treatment reduced blood loss by 35% in type 2B VWD mice and 68% in vWF knockout mice. These findings suggest that SPs may offer a promising therapeutic approach for managing bleeding in vWD. In vitro studies on SynthoPlate assessed its impact on thrombin and fibrin generation to evaluate its procoagulant potential. SynthoPlate did not induce spontaneous thrombin generation in human plasma but enhanced fibrin deposition under flow conditions by promoting platelet recruitment and aggregation on a collagen and vWF-coated surface. In vivo, a thrombocytopenic mouse model was used to assess SynthoPlate's hemostatic efficacy. Mice treated with SynthoPlate exhibited significantly reduced bleeding times following tail transection compared to controls, with effects observed within a two-hour circulation period. Immunostaining and immunoblotting confirmed enhanced fibrin formation at the injury site, indicating that SynthoPlate effectively supports clot formation in platelet-deficient conditions.
Lurasidone is taken by mouth and should be taken with a meal of at least 350 calories to ensure maximum absorption. It has an estimated absorption rate of 9 to 19%. Studies have shown that when lurasidone is taken with food, absorption increases about twofold. Peak blood plasma concentrations are reached after one to three hours. About 99% of the circulating substance are bound to plasma proteins. Efficacy data for lurasidone have been evaluated for doses of 20 mg to 120 mg daily. In schizophrenia, lurasidone has a recommended dose range of 40-160 mg. In bipolar depression, lurasidone has a slightly lower recommended dose range of 20-120 mg. Lurasidone is extensively metabolised by CYP3A4 leading to contraindication of both strong inhibitors as well as strong inducers of this enzyme, but has negligible affinity to other cytochrome P450 enzymes. It is transported by P-glycoprotein and ABCG2 and also inhibits these carrier proteins in vitro. It also inhibits the solute carrier protein SLC22A1, but no other relevant transporters. Main metabolism pathways are oxidative N-dealkylation between the piperazine and cyclohexane rings, hydroxylation of the norbornane ring, and S-oxidation.:59 Other pathways are hydroxylation of the cyclohexane ring and reductive cleavage of the isothiazole ring followed by S-methylation. The two relevant active metabolites are the norbornane hydroxylation products called ID-14283 and ID-14326, the former reaching pharmacologically relevant blood plasma concentrations.
In the cooking process, Maillard reactions can produce hundreds of different flavor compounds depending on the chemical constituents in the food, the temperature, the cooking time, and the presence of air. These compounds, in turn, often break down to form yet more flavor compounds. Flavorists have used the Maillard reaction over the years to make artificial flavors, the majority of patents being related to the production of meat-like flavors. According to chemistry Nobel Prize winner Jean-Marie Lehn "The Maillard is, by far, the most widely practiced chemical reaction in the world".
==== Mazdaspeed Protegé ==== For the 2001 model year in North America, Mazda introduced the limited-edition Protegé MP3 featuring a new sport-tuned suspension, 17-inch Racing Hart wheels, and a 10 hp (7 kW) gain for a total of 140 hp (104 kW), which was achieved through a tuned factory ECU which advances ignition timing requiring high octane rating petrol, cat-back exhaust by Racing Beat, and removal of the Mazda VTCS system. The MP3 also came from the factory with a complete 450-watt Kenwood powered MP3 stereo with 10-inch (250 mm) powered subwoofer. A total of 1,500 were produced – 1,000 finished in blue, and 500 painted yellow. 2001 saw the North American introduction of the hatchback, called Protegé5 with the same 2.0 L engine offering 130 hp (97 kW; 132 PS) / 135 lb⋅ft (183 N⋅m) this year and a slightly revised interior. In 2002, most Protegés (including the 5) received the 2.0 L engine, although the SE in Canada had the 1.6 L. In 2003, Mazdaspeed introduced the Mazdaspeed Protegé, an update to the Protegé MP3 that had a 170 hp (127 kW; 172 PS) / 160 lb⋅ft (217 N⋅m) turbocharged engine, shared the MP3's full Racing Beat suspension, redesigned 17-inch (430 mm) wheels, larger four-wheel disc brakes, and a Kenwood stereo system that included an amplifier along with a rear-deck mounted 8-inch (200 mm) sub. Mazda then followed with a mid year change dubbed the "2003.5." This model included a different aero-kit, the same 17-inch (430 mm) Racing Hart wheels, but with a darker color, and custom interior pieces.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.